ConSynance Therapeutics is a clinical-stage biopharmaceutical company targeting rare central nervous system diseases.  We aim to turn breakthrough science into transformative therapies for patients, with our focus on diseases related to hypothalamic dysregulation, including Prader-Willi Syndrome, hypothalamic injury-induced obesity, and other neurological disorders.